



Patent Application
Attorney Docket No. PC11696A

I hereby certify that this correspondence is being deposited as first-class mail with the United States Postal Service, and is addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of June, 2004.

By _____

(Signature of person transmitting)

A. David Jordan

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gene Michael Bright :

APPLICATION NO.: 10/766,741 : Examiner:

FILING DATE: January 27, 2004 : Group Art Unit:

TITLE: SHT7 ANTAGONISTS AND INVERSE
AGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date:

June 1, 2004

Respectfully submitted,


A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733-3381



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC11696A		SERIAL NO. 10/766,741					
								APPLICANT Gene Michael Bright							
								FILING DATE January 27, 2004		GROUP					
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	US	5	1	6	2	3	3	9	11/10/92	John A. Lowe					
	US	5	2	3	2	9	2	9	8/3/93	Manoj C. Desai					
FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
	EP	0	4	9	9	3	1	3	11/6/97	EPO					
	EP	0	5	2	0	5	5	5	01/9/99	EPO					
	WO	0	2	2	1	6	7	1	12/10/92	PCT					
	WO	9	3	0	0	3	3	1	01/7/93	PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
			Richard A. Glennon, "Serotonin Receptors: Clinical Implications", Neuroscience & Biobehavioral Reviews, 14, pp 35-47, (1990)												
			Yoram Solomon et. al., "A Highly Sensitive Adenylate Cyclase Assay", Analytical Biochemistry, 58, pp 541-48, (1974)												
			B. Kenneth Koe et. al., "Sertraline, 1S,4S-N-Methyl-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthylamine, a New Uptake Inhibitor with Selectivity for Serotonin", J. Pharmacology & Experimental Therapeutics, 226, pp 686-700, (1983)												
EXAMINER				DATE CONSIDERED											
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>															

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE